scholarly journals PENTOSAN POLYSULPHATE INFLUENCEON THE COURSE OF CHRONICKIDNEYDISEASE ST'. II - IV

2015 ◽  
pp. 10-16
Author(s):  
O. Dudari ◽  
M. Shifrisi ◽  
V.Ye. Driyanska ◽  
V.F. Krot ◽  
O.M. Loboda ◽  
...  
Keyword(s):  
Inflammatory Cytokines ◽  
Standard Therapy ◽  
Comparison Group ◽  
Lipid Lowering ◽  
Hypolipidemic Effect ◽  
Vascular Endothelial ◽  
Before And After ◽  
Pentosan Polysulphate ◽  
Group 2 ◽  
Endothelial Growth Factor

The aim is to determine the effect of the drug pentosan polysulphate at the rate of disease progression in patients with CKD II - IVst., to confirmation of lipid - lowering action and setting of the drug on indicators of chronic inflammation. Materials and methods. Tests conducted in one center for 12 weeks. The study included 60patients with CKD II - IV st. Patients were divided into 2 groups: group 1 (basic) - 30patients in addition to standard therapy receiving study medication, pentosan polysulphate, group 2 - 30 patients received only standard therapy. The drug pentosan polysulphate was administered for 8 - weeks: 100 mg. a day intramuscularly or intravenously for 3 weeks, followed by oral administration of 50 mg two times a day. The survey studied the dynamics ofdaily proteinuria, GFR, lipids, indicators of tumor necrosis factor, IL - 18 and vascular endothelial growth factor (VEGF) before and after treatment (12 week observation). Results. It was found a significant decrease in total cholesterol and atherogenic ratio after 3 months of treatment in the study group, hypolipidemic effect is more significant than in the comparison group. The group used pentosan polysulphate proteinuria reduction was more pronounced, and was 65% against 38% in the comparison group. Pentosan polysulphate in the treatment ofCKDpatients in stages II - IV contributes to significant decrease in inflammatory cytokines (IL - 18 and TNF - a) in contrast to the comparison group. Conclusions. The use of pentosan polysulphate in the treatment of patients with CKD stages II - IV had positive effect on lipid metabolism. Purpose pentosan polysulphate patients with CKD stages II - IV contributes to a significant reduction of the daily proteinuria and eGFR improvement, reduces levels of inflammatory cytokines: IL - 18 and TNF - a.  

scholarly journals Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takehiro Matsumura ◽  
Kentaro Iwasaki ◽  
Shogo Arimura ◽  
Ryuji Takeda ◽  
Yoshihiro Takamura ◽  
...  
Keyword(s):  
Growth Factor ◽  
Inflammatory Cytokines ◽  
Aqueous Humour ◽  
Ophthalmic Solution ◽  
Vascular Endothelial ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Before And After ◽  
Endothelial Growth Factor ◽  
Single Blind

AbstractIntraocular surgery is associated with increased ocular inflammation. If maintained for a prolonged period after surgery, this inflammation can cause various complications, including subconjunctival fibrosis and bleb scarring. This clinical trial was a prospective, randomised, single-blind, interventional study comparing the efficacy and safety of 0.1% bromfenac sodium ophthalmic solution and 0.02% fluorometholone ophthalmic suspension in the inhibition of multiple inflammatory cytokines in the aqueous humour of 26 patients with pseudophakic eyes who had undergone phacoemulsification and intraocular lens implantation. The patients were randomly assigned to one of the trial drugs, and aqueous humour samples were collected before and after drug administration. Platelet-derived growth factor-AA levels significantly decreased in both drug groups, but they were significantly higher in the fluorometholone group than in the bromfenac group (P = 0.034). Bromfenac also significantly decreased vascular endothelial growth factor level (P = 0.0077), as well as monocyte chemoattractant protein-1 level (P = 0.013), which was elevated for a prolonged period after phacoemulsification. These data suggest that bromfenac is useful to alleviate prolonged microenvironmental alterations in the aqueous humour of pseudophakic eyes.

The optimization of reparative processes after cesarean section (clinical-experimental research)

2015 ◽  
Vol 64 (4) ◽  
pp. 4-12 ◽  
Author(s):  
Edvard Karpovich Aylamazyan ◽  
Victoriya Yuryevna Andreeva ◽  
Tatiana Ulyanovna Kuzminykh ◽  
Dmitriy Igorevich Sokolov ◽  
Sergey Alekseevich Selkov ◽  
...  
Keyword(s):  
Pregnant Woman ◽  
Cesarean Section ◽  
Comparison Group ◽  
Main Group ◽  
Control Group ◽  
Collagen Membrane ◽  
Vascular Endothelial ◽  
Actual Direction ◽  
Uterine Scar ◽  
Endothelial Growth Factor

Development and introduction of materials influenced on reparation process in a myometrium is actual direction of modern obstetrics in connection with the increase of cesarean section rate. One of such preparation is «Collost», it stimulates the processes of neoangio- and myogenesis and excludes the disorderly growth of scars tissue. Aim: To study the influence of bioplastic material «Collost» on the reparation process in myometrium after cesarean section. Objectives: to estimate the morpho-functional state of scar on uterus after cesarean sections depending on implantation of collagen membrane. Material and methods: There were included 13 female rabbits in experimental part of the study. In clinical part of the study there were included 20 pregnant woman with intraoperative application of «Collost» (main group), 30 pregnant woman without «Collost» implantation (comparison group) and 10 pregnant with vaginal delivery (control group). Results: histological, immunohistological and immunological findings of postoperative uterine scars of female rabbits showed significant differences of expressions of miosin, vascular endothelial growth factor and collagen I type. The myometrium was significantly thicker in the area of uterine scar in main group (with collagen membrane implantation) than in comparison group. Conclusions: bioplastic material «Collost» leads to full formation of muscular wall and vascular ture in the area of postoperative uterine scar.

In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 3558-3558
Author(s):  
D. Santini ◽  
B. Vincenzi ◽  
F. Battistoni ◽  
S. Galluzzo ◽  
L. Rocci ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Low Doses ◽  
Dose Administration ◽  
Before And After ◽  
Endothelial Growth Factor ◽  
First Time

3558 Purpose: Recent data have demonstrated in preclinical tumor models an antiangiogenic and antitumor activity of low weekly doses of ZA. As a consequence, the purpose of this study was to confirm these data, evaluating in cancer patients the modifications in angiogenic cytokines levels following repeated weekly low doses of ZA. Experimental Design: 26 consecutive cancer patients with bone metastases treated, for the first time, with four weekly doses of 1 mg of ZA followed by standard doses (4 mg every 28 days) were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) at different time points: just before and after 1, 7, 14, 21, 28, 56 and 84 days following the first disphosphonate infusion. Results: Basal serum VEGF median levels were significantly decreased just after 7 days (-29.7%) (with only one weekly infusion) (P=0.038), This significant decrease of circulating VEGF levels persisted 14(-33.2%), 21 (-39.4%), 28(-31.8%), 56(-33.6%) and 84(-27.9%) days after the first infusion (respectively, P=0.002, P=0.001, P=0.008, P=0.002, P=0.014). Conclusions: This study confirms, for the first time in humans, that weekly low doses of zoledronic acid could have antiangiogenic properties through a significant and long lasting decrease of VEGF serum levels. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document